Breaking News, Financial News

Financial Report: Roche 3Q

Pharmaceutical sales were up 2% attributed to Avastin, MabThera/Rituxan, Herceptin, Lucentis, Actemra/RoActemra and Xeloda.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche 3Q 3Q Revenues: $12.1 billion (+2%) YTD Revenues: $37.0 billion (+3%) Comments: Pharmaceutical sales were up 2% attributed to Avastin, MabThera/Rituxan, Herceptin, Lucentis, Actemra/RoActemra and Xeloda. Sales of cancer medicines were up 8% in the quarter. Revenues in the quarter were negatively impacted by lower demand for Tamiflu. Roche’s Diagnostics Division revenue was up 9% driven mainly by professional diagnostics and diabetes care....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters